Anatoliy P. Kazantsev

Anatoliy P. Kazantsev

Auto-generated profile, based on publicly available information

Anatoliy P. Kazantsev

N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Oncopediatrics
Verified
Journal Article
Open access
PDF file
AKA. V. Khizhnikov
A. V. Khizhnikov
AKA. P. Kazantsev
A. P. Kazantsev
ЛЕЧЕНИЕ ПАЦИЕНТОВ С НЕЙРОБЛАСТОМОЙ ГРУППЫ ВЫСОКОГО РИСКА

1 January 2016 in Oncopediatrics
Verified
Journal Article
Open access
PDF file
PKP. A. Kerimov
P. A. Kerimov
AKA. P. Kazantsev
A. P. Kazantsev
MRM. A. Rubansky
M. A. Rubansky
MRM. V. Rubanskaya
M. V. Rubanskaya
RPR. I. Pimenov
R. I. Pimenov
AРArray А. Рубанский
Array А. Рубанский
СОЛИДНО-ПСЕВДОПАПИЛЛЯРНАЯ ОПУХОЛЬ ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ У ПАЦИЕНТОВ ДЕТСКОГО ВОЗРАСТА: ОБЗОР ЛИТЕРАТУРЫ

15 September 2017 in Regional Anesthesia and Acute Pain Management
Verified
Journal Article
Open access
PDF file
NMNune V. Matinyan
Nune V. Matinyan
ILI. A Letyagin
I. A Letyagin
LML. A Martynov
L. A Martynov
ASA. V Sotnikov
A. V Sotnikov
AKA. P Kazantsev
A. P Kazantsev
РВРыбакова Д. В
Рыбакова Д. В
Epidural administration of opioids effectively prevents the sensitization of nociceptive neurons of the posterior horn of the spinal cord, induced by surgical trauma, without the development of motor and autonomic blockade. Study includes 52 patients aged 1 month to 18 years with malignant tumors who underwent surgical treatment at the Pediatric Oncology and Hematology Research Institute, during 2009-2016 years. Surgeries were combined (thoraco-laparotomy). The method of epidural use of morphine in pediatric oncosurgery is presented.

22 January 2020 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
ASA. M. Stroganova
A. M. Stroganova
MRM. V. Rubanskaya
M. V. Rubanskaya
GCG. Yu. Chemeris
G. Yu. Chemeris
SDS. L. Dranko
S. L. Dranko
AKA. I. Karseladze
A. I. Karseladze
AKA. P. Kazantsev
A. P. Kazantsev
Белок CRABP1 как один из возможных факторов прогноза у детей с нейробластомой группы высокого риска

23 April 2025 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
KSK. A. Sergeenko
K. A. Sergeenko
EME. B. Machneva
E. B. Machneva
TAT. Z. Aliev
T. Z. Aliev
NBNatalia Burlaka
Natalia Burlaka
OKO. A. Kapkova
O. A. Kapkova
SVS. R. Varfolomeeva
S. R. Varfolomeeva
Germ cell tumors (GCTs) are a heterogeneous group of tumors that develop from pluripotent germ cells, diagnosed most often in infants, young children, adolescents and young adults, and are characterized by different localization, histological picture, clinical course and prognosis. Despite the fairly high efficiency of modern standard chemotherapy protocols for GCTs, the treatment of their relapses and refractory forms, which make up to 30–40 % of all GCTs and have an extremely unfavorable prognosis, is very difficult. Currently, there is no single strategy for the treatment of relapses and refractory forms of GCTs, however, the world and domestic literature presents data on the successful use of high-dose chemotherapy (HDCT) in such patients followed by autologous hematopoietic stem cell transplantation (auto-HSCT). To develop and optimize protocols for this therapy method, and therefore improve the treatment outcomes for patients with relapses and refractory forms of GCT, it is necessary to analyze a larger number of studies from various transplant centers working in this area. The article presents current literature data on the use of HDCT followed by auto-HSCT in patients with GCT, as well as a clinical case of successful 2 courses of HDCT with auto-HSCT in tandem mode in a child with a refractory form of GCT with subsequent maintenance of complete remission for 2 years.

21 July 2024 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
TAT. Z. Aliev
T. Z. Aliev
KKKirill Kirgizov
Kirill Kirgizov
EME. B. Machneva
E. B. Machneva
IKIrina Kostareva
Irina Kostareva
KSK. A. Sergeenko
K. A. Sergeenko
SVS. R. Varfolomeeva
S. R. Varfolomeeva
High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is a therapeutic option that allows potentiating the antitumor effect in patients with malignant neoplasms (MNs) belonging to the high-risk group. However, despite the effectiveness of this method, the risks of developing infectious and toxic complications in the early and late post-transplantation period are higher than the risks associated with treatment according to standard protocols and can significantly worsen the results of transplantation. We carried out a retrospective analysis of the results of auto-HSCT in a cohort of 156 patients with high-risk solid MNs treated at the L.A. Durnov Research Institute of Pediatric Oncology and Hematology, the N.N. Blokhin National Medical Research Center of Oncology of Ministry of Healthcare of the Russian Federation in 2020–2023. The study was approved by the Independent Ethics Committee and the Scientific Council of the N.N. Blokhin National Medical Research Center of Oncology. The study included 78 (50%) boys and 78 (50%) girls, the median age of the patients was 8 years 7 months (9 months – 17 years 8 months). Auto-HSCT was performed in 90 (57.7%) patients with neuroblastoma, 25 (16.0%) – with Ewing's sarcoma, 16 (10.3%) – with germ cell tumors, 13 (8.4%) – with nephroblastoma, 7 (4.5%) – with retinoblastoma, 3 (1.9%) – with medulloblastoma, 1 (0.6%) patient with pleuropulmonary blastoma and 1 (0.6%) patient with sialoblastoma. We used the following conditioning regimens: treosulfan + melphalan (n = 116), carboplatin + thiotepa + etoposide (n = 17), melphalan (n = 13), carboplatin + thiotepa + etoposide + cyclophosphamide (n = 10). Depending on the clinical indications and the treatment protocol used, 136 (87.2%) patients underwent one course of HDCT, and 20 (12.8%) patients underwent tandem HDCT. In most patients, the median recovery time for granulocytes and platelets was 11 (8–19) days and 14 (12–21) days, respectively. The most common infectious complications in patients after auto-HSCT were mucositis (89.1%), neutropenic enterocolitis (76.9%), febrile neutropenia (71.2%), less often: catheter-associated bloodstream infection (9%), pneumonia (14.1%), acute respiratory distress syndrome (0.6%). As regards toxic complications, all patients had emetic syndrome, 98 (62.8%) had dermatological toxicity, 9 (5.8%) had hemorrhagic cystitis, 116 (74.3%) had hepatic toxicity, 14 (9%) had neurotoxicity, 102 (65.4%) had moderate nutritional insufficiency. Episodes of hemorrhagic syndrome due to thrombocytopenia were observed in 44.2% of patients. After auto-HSCT, most patients develop chemotherapy-induced (including infectious) complications, which can not only significantly disrupt the patients’ well-being and quality of life, but also, depending on the severity, pose a threat to their life. The correct choice of conditioning regimen, effective collection of hematopoietic stem cells, complex accompanying therapy, timely diagnosis and treatment of complications can significantly improve the results of auto-HSCT in children with high-risk solid MNs.